The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review
Authors: Zhaocong Chen
Junyan Cao
Zhiming He
Jianlong Ding
Journal: Bioengineered (2020)
Discipline: BIOLOGY & BIOCHEMISTRY
Keywords: LINC00511; metastasis; prognosis; tumor.
Affiliations: Department of Hepatobiliary Surgery, 3201 Hospital of Xi‚Äôan Jiaotong University Health Science Center, Shanxi Xi‚Äôan, China, Department of Medical Ultrasonic, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China, Department of Rehabilitation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China, General Surgery, Chongqing Red Cross Hospital, Jialing No.1 Village, Jiangbei District, Chongqing, China

Abstract:  Increasing studies suggested that long intergenic noncoding RNA 00511 (LINC00511) could facilitate the progression of various malignancies and correlates with prognosis of patients with malignant tumors. However, its clinical significance is still not completely clarified. Therefore, we performed a meta-analysis and bioinformatics analysis to further evaluate the correlation of LINC00511 expression level with prognosis and metastasis in patients with tumors. The pooled hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the prognostic significance of LINC00511 expression level. The pooled odds ratio (OR) with 95% CI was applied to assess the association between LINC00511 expression level and tumor metastasis. A total of 12 studies involving 1040 tumor patients were included in this meta-analysis. The pooled analyses suggested that higher LINC00511 expression level correlated with worse overall survival (OS) (HR = 1.93, 95% CI 1.49-2.49, P &lt; 0.001) and higher incidence of lymph node metastasis (OR = 3.07, 95% CI 2.23-4.23, P &lt; 0.001). Additionally, bioinformatics analysis based on TCGA datasets also showed that increased LINC00511 expression level may predict poor OS and disease-free survival (DFS) in patients with malignant tumors. Taken together, our finding suggested that high LINC00511 expression level may be correlated with poor prognosis and high incidence of metastasis. Nevertheless, further large-scale and high-quality studies are needed to validate our findings. 

Retracted: No

PubPeer comments:
  Finally, a total of 12 eligible studies were included in this meta-analysis [7u201315,18,19]. It appears from the tables that the 12th eligible study was [22].  All the included studies were given with no less than six scores based on NOS criteria, suggesting that they were moderate to high quality and eligible for this meta-analysis. Ref. [9] is [Liu L, Zhu Y, Liu A-M, et al (2019). Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185. Eur Rev Med Pharmacol Sci.] . It contains experimental images that occur in numerous other papers, in a way that is consistent with the products of a papermill, raising serious doubts that the research it reports ever occurred. Ref [18] is [Deng H, Huang C, Wang Y, et al. (2019), LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression. Aging (Albany NY)] . It contains flow-cytometry plots from a suite that features in a score of other papers, in a way that is consistent with the products of a papermill, raising serious doubts that the research it reports ever occurred. Two questions come to mind. How much would the authors conclusions change, if these two problematic papers were omitted? Secondly, how much confidence do the authors retain for the remaining 10 papers? ,